The experimental Alzheimer’s disease drug from San Francisco-based Medivation Inc. (NASDAQ: MDVN) failed a late-stage trial, the company said Monday, and Medivation and partner Pfizer Inc. (NYSE: PFE) said they will discontinue development in all diseases.
Dimebon’s demise also will shut down another ongoing study of the small, green tablet in Alzheimer’s patients.
Dimebon failed a high-profile Alzheimer’s trial in 2010 and a late-stage trial in Huntington’s disease last year.
No comments:
Post a Comment